Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors

Abstract

BackgroundBreast cancer tumors are known to be highly heterogeneous and differences in their metabolic phenotypes, especially at protein level, are less well-understood. Profiling of metabolism-related proteins harbors the potential to establish new patient stratification regimes and biomarkers promoting individualized therapy. In our study, we aimed to examine the relationship between metabolism-associated protein expression profiles and clinicopathological characteristics in a large cohort of breast cancer patients.MethodsBreast cancer specimens from 801 consecutive patients, diagnosed between 2009 and 2011, were investigated using reverse phase protein arrays (RPPA). Patients were treated in accordance with national guidelines in five certified German breast centers. To obtain quantitative expression data, 37 antibodies detecting proteins relevant to cancer metabolism, were applied. Hierarchical cluster analysis and individual target characterization were performed. Clustering results and individual protein expression patterns were associated with clinical data. The Kaplan-Meier method was used to estimate survival functions. Univariate and multivariate Cox regression models were applied to assess the impact of protein expression and other clinicopathological features on survival.ResultsWe identified three metabolic clusters of breast cancer, which do not reflect the receptor-defined subtypes, but are significantly correlated with overall survival (OS, p ≤ 0.03) and recurrence-free survival (RFS, p ≤ 0.01). Furthermore, univariate and multivariate analysis of individual protein expression profiles demonstrated the central role of serine hydroxymethyltransferase 2 (SHMT2) and amino acid transporter ASCT2 (SLC1A5) as independent prognostic factors in breast cancer patients. High SHMT2 protein expression was significantly correlated with poor OS (hazard ratio (HR) = 1.53, 95% confidence interval (CI) = 1.10–2.12, p ≤ 0.01) and RFS (HR = 1.54, 95% CI = 1.16–2.04, p ≤ 0.01). High protein expression of ASCT2 was significantly correlated with poor RFS (HR = 1.31, 95% CI = 1.01–1.71, p ≤ 0.05).ConclusionsOur data confirm the heterogeneity of breast tumors at a functional proteomic level and dissects the relationship between metabolism-related proteins, pathological features and patient survival. These observations highlight the importance of SHMT2 and ASCT2 as valuable individual prognostic markers and potential targets for personalized breast cancer therapy.Trial registrationClinicalTrials.gov, NCT01592825. Registered on 3 May 2012.Electronic supplementary materialThe online version of this article (doi:10.1186/s13058-017-0905-7) contains supplementary material, which is available to authorized users.

Potent Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT) Featuring a Spirocyclic Scaffold

“…Human cytosolic SHMT1 and mitochondrial SHMT2 are of emerging interest as potential anticancer targets . We therefore tested the potent spiro‐dihydroindene analogues against h SHMT1 (Table ).…”

TGFβ1 regulates HGF‐induced cell migration and hepatocyte growth factor receptor MET expression via C‐ets‐1 and miR‐128‐3p in basal‐like breast cancer

“…Tissue lysates from fresh‐frozen breast cancer patient samples were derived from the multicenter prospective PiA study (NCT01592825) as previously described (Bernhardt et al ., 2017). Breast cancer subtypes were defined to histopathological characteristics such as receptor status and grading according to the St. Gallen classification and by von Minckwitz and colleagues (Goldhirsch et al ., 2013; von Minckwitz et al ., 2012).…”

PI3K: A master regulator of brain metastasis‐promoting macrophages/microglia

“…RPPAs were produced as previously described in Bernhardt et al (2017). Prior to printing the samples on nitrocellulose-coated glass slides (Oncyte Avid, Grace-Biolabs, USA), protein concentrations were adjusted to 0.8 μg/μl using 6× SDS sample buffer (15% Glycerol, 187.5 mM Tris-HCl, 6% SDS) containing 15 mM DTT and boiled for 5 min at 95 C. For detailed information about antibodies used see Supporting Information Table S3. RPPA data was analyzed with the R package "RPPanalyzer" (version 1.4.3; Mannsperger, Gade, Henjes, Beissbarth, & Korf, 2010;von der Heyde et al, 2014).…”